- Home
- CLLS vs PTMN Comparison
CLLS vs PTMN Comparison
Compare CLLS & PTMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- PTMN
- Stock Information
- Founded
- CLLS 1999
- PTMN 2006
- Country
- CLLS France
- PTMN United States
- Employees
- CLLS 216
- PTMN N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- PTMN Finance: Consumer Services
- Sector
- CLLS Health Care
- PTMN Finance
- Exchange
- CLLS Nasdaq
- PTMN Nasdaq
- Market Cap
- CLLS 148.1M
- PTMN 156.9M
- IPO Year
- CLLS 2007
- PTMN N/A
- Fundamental
- Price
- CLLS $1.48
- PTMN $16.42
- Analyst Decision
- CLLS Buy
- PTMN Hold
- Analyst Count
- CLLS 3
- PTMN 3
- Target Price
- CLLS $7.00
- PTMN $19.33
- AVG Volume (30 Days)
- CLLS 235.1K
- PTMN 37.9K
- Earning Date
- CLLS 11-04-2024
- PTMN 03-12-2025
- Dividend Yield
- CLLS N/A
- PTMN 16.81%
- EPS Growth
- CLLS N/A
- PTMN N/A
- EPS
- CLLS N/A
- PTMN 0.39
- Revenue
- CLLS $36,042,000.00
- PTMN $65,828,000.00
- Revenue This Year
- CLLS $387.77
- PTMN N/A
- Revenue Next Year
- CLLS $11.14
- PTMN N/A
- P/E Ratio
- CLLS N/A
- PTMN $42.56
- Revenue Growth
- CLLS 46.96
- PTMN N/A
- 52 Week Low
- CLLS $1.41
- PTMN $15.94
- 52 Week High
- CLLS $3.38
- PTMN $20.84
- Technical
- Relative Strength Index (RSI)
- CLLS 38.66
- PTMN 48.10
- Support Level
- CLLS $1.65
- PTMN $16.05
- Resistance Level
- CLLS $2.23
- PTMN $16.38
- Average True Range (ATR)
- CLLS 0.18
- PTMN 0.24
- MACD
- CLLS -0.03
- PTMN 0.04
- Stochastic Oscillator
- CLLS 8.54
- PTMN 84.21
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About PTMN Portman Ridge Finance Corporation
Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt primarily in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.